Medivir Secures $4.9 Million Investment from Carl Bennet AB
Swedish pharmaceutical company Medivir has completed a directed new share issue, raising 45 million Swedish krona (approximately $4.9 million USD) from Carl Bennet AB, according to recent company announcements.
The investment has already begun to impact Medivir’s market performance, with the company’s stock price rising following the announcement of Bennet’s stake. Carl Bennet AB is now a major shareholder in the drug development firm.
Medivir focuses on the discovery and development of innovative cancer treatments, specifically targeting areas with high unmet medical needs. The company’s research and development efforts are centered around expertise in protease inhibitor design and nucleotide science, as detailed on their About Us page.
According to reports, Carl Bennet’s investment has already yielded a significant return, with gains of 18 million Swedish krona reported. This highlights investor confidence in Medivir’s potential and the strategic value of the partnership.
The company is currently advancing several projects, including Fostroxacitabine bralpamide (fostrox), a nucleotide DNA polymerase inhibitor in oral form. Medivir also emphasizes collaborative partnerships with academic and industrial partners to enhance its research and development capabilities, as noted on Medivir’s website.
Medivir is scheduled to release its Year-End Report for January-December 2025 on February 18, 2026, followed by an Interim Report for January-March 2026 on April 29, 2026, and an Interim Report for January-June 2026 on August 20, 2026. These reports will provide further insight into the company’s financial performance and strategic direction. More information on upcoming events can be found on the News and Media section of their website.
This investment underscores the continued interest in the pharmaceutical sector and the potential for growth in innovative cancer therapies.
